An expert-driven program addressing the optimal treatment strategy for patients with a targetable EGFR mutation.
This independent medical education comprises a webcast and a treatment pathway tool.
Suitable for oncologists and other HCPs involved in the diagnosis, treatment, and follow-up of patients with lung cancer.

Why might this benefit you?

With the increasing number of treatment options available for patients with EGFR mutation-positive mNSCLC, the challenge clinicians now face is the identification of optimal treatment strategies for each individual patient. 

This program is designed to support clinicians to make the best choices for individualized treatment, while addressing the importance of comprehensive genomic testing and diagnosis and the early characterization of tumors. In addition, the program highlights how an increased understanding of the different mechanisms behind resistance can help to predict and/or prevent its occurrence.

What will the program look like?
60 minute webcast
Dr Socinski will be joined by US Faculty to discuss and provide guidance on the characterization of EGFR mutation-positive tumor subtypes, appropriate sequencing of treatment and management of EGFR TKI resistance.
Treatment pathway tool

Guided by our program director, Dr Socinski, physicians can follow the patient journey by navigating a multimedia pathway through first-line treatment into options for potential progression, supported by trial data and expert opinion.

Dr Mark A Socinski

Advent Health Cancer Institute, FL, USA

Mark A Socinski is the Executive Medical Director of the Advent Health Cancer Institute in Orlando, FL. He received his medical degree from the University of Vermont, College of Medicine, and he completed his postdoctoral training including an internship and residency in internal medicine at the Beth Israel Hospital, and medical oncology fellowship at the Dana-Farber Cancer Institute, both at Harvard Medical School.

Dr Socinski has held posts as Director of the Lung Cancer Section at the University of Pittsburgh Medical Center, Clinical Associate Director of the University of Pittsburgh Lung Cancer Specialized Program of Research Excellence (SPORE), Co-Director of UPMC Lung Cancer Center of Excellence, and Co-Leader of the Lung Cancer Program at the University of Pittsburgh Cancer Institute. He is a member of numerous professional societies, such as the American College of Physicians (ACP), American Society of Clinical Oncology (ASCO), Cancer and Leukemia Group B (Alliance), International Association for the Study of Lung Cancer (IASLC), and American College of Chest Physicians.

Dr Socinski is also co-Chair Emeritus of the Thoracic Malignancies Steering Committee for the National Cancer Institute. Dr Socinski is well-published in peer-reviewed literature, including the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer, and The Lancet Oncology. His primary research interests cover all aspects of clinical trials related to the thoracic oncology population. He also has been instrumental in the development of many cooperative group and investigator-initiated clinical trials.

Disclosures

Dr Socinski discloses that he has received grant support, honoraria and/or served on a speakers’ bureau for Genentech, Novartis, AstraZeneca, Spectrum, Guardant Health, and Bayer.

Professor Edward Garon

David Geffen School of Medicine, UCLA, CA, USA

Edward Garon is the Director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. Professor Garon performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently Professor of Medicine. He also received a Master’s degree in clinical investigation from UCLA.

Professor Garon has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Disclosures

Dr Garon discloses financial/non-financial relationships with Dracen, GSK, EMD Serono, Merck, Genentech, and Novartis and has received research grants from Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Genotech, Neon Therapeutics, Iovance Biotherapeutics, Dynavax and Mirati Therapeutics.

Dr Leora Horn

Vanderbilt-Ingram Cancer Center, TN, USA

Leora Horn is an Ingram Associate Professor of Cancer Research and the Director of the Thoracic Oncology Research Program at Vanderbilt Ingram Cancer Center (VICC) in Nashville, Tennessee. She is also the Assistant Vice Chairman for Faculty Development at Vanderbilt University Medical Center. Her clinical practice focuses on the care of patients with lung cancer. 

Dr Horn is an active member of the Eastern Cooperative Oncology Group, International Association for the Study of Lung Cancer and the American Society of Clinical Oncology. She has over 150 publications and in the last eight years, she has been among the top 5 in accrual to clinical trials at VICC where she has a focus on clinical trials with targeted therapies and immunotherapy as well as small cell lung cancer. Dr Horn works closely with many collaborators at VICC translating laboratory findings into clinical trials for patients with lung cancer.

Disclosures

Dr Horn discloses financial/non-financial relationships with Astra Zeneca, Amgen, Incyte, EMD Serono, Merck, Genentech, Tessaro, Xcovery, Pfizer, Abbvie. She has also received research grants from BMS, Xcovery and BI.

After participating in the program, learners will be able to:

  • Select the optimal treatment strategy for patients with a targetable EGFR mutation
  • Recognize the importance of early and comprehensive genomic testing
  • Interpret the test results to make more individualized treatment decisions
  • Describe the mechanisms behind EGFR tyrosine kinase inhibitor (TKI) resistance and how to predict and manage this

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.

The program will be certified with AMA PRA Category 1 Credits™; the amount of credits are shown below. Participants should claim only credits commensurate with the extent of their participation in the activities.

The following activities will be accredited:

  • 60 minute webcast: a maximum of 1 AMA PRA Category 1 Credit
  • Treatment pathway: a maximum of 2 AMA PRA Category 1 Credits

At the end of the activity, please fill out the evaluation form and select “I wish to claim credits” and after completion you will be able to collect your CME certificate.

NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Planning committee

In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include Chris Bolwell, Jules Morgan, Rebecca Cox, and Alba Ruzafa. Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service. Jules Morgan, Rebecca Cox, and Alba Ruzafa have no financial relationships to disclose.

This activity is supported by an educational grant from Lilly.

Related content

Led by experts and designed for you to help navigate the different treatment lines of non-driver NSCLC.

Sign up for alerts!

Stay informed about new content related to this activity
Faculty
Professor Edward Garon

David Geffen School of Medicine, UCLA, CA, USA

Edward Garon is the Director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. Professor Garon performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently Professor of Medicine. He also received a Master’s degree in clinical investigation from UCLA.

Professor Garon has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Disclosures

Dr Garon discloses financial/non-financial relationships with Dracen, GSK, EMD Serono, Merck, Genentech, and Novartis and has received research grants from Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Genotech, Neon Therapeutics, Iovance Biotherapeutics, Dynavax and Mirati Therapeutics.

Dr Leora Horn

Vanderbilt-Ingram Cancer Center, TN, USA

Leora Horn is an Ingram Associate Professor of Cancer Research and the Director of the Thoracic Oncology Research Program at Vanderbilt Ingram Cancer Center (VICC) in Nashville, Tennessee. She is also the Assistant Vice Chairman for Faculty Development at Vanderbilt University Medical Center. Her clinical practice focuses on the care of patients with lung cancer. 

Dr Horn is an active member of the Eastern Cooperative Oncology Group, International Association for the Study of Lung Cancer and the American Society of Clinical Oncology. She has over 150 publications and in the last eight years, she has been among the top 5 in accrual to clinical trials at VICC where she has a focus on clinical trials with targeted therapies and immunotherapy as well as small cell lung cancer. Dr Horn works closely with many collaborators at VICC translating laboratory findings into clinical trials for patients with lung cancer.

Disclosures

Dr Horn discloses financial/non-financial relationships with Astra Zeneca, Amgen, Incyte, EMD Serono, Merck, Genentech, Tessaro, Xcovery, Pfizer, Abbvie. She has also received research grants from BMS, Xcovery and BI.

Program director
Dr Mark A Socinski

Advent Health Cancer Institute, FL, USA

Mark A Socinski is the Executive Medical Director of the Advent Health Cancer Institute in Orlando, FL. He received his medical degree from the University of Vermont, College of Medicine, and he completed his postdoctoral training including an internship and residency in internal medicine at the Beth Israel Hospital, and medical oncology fellowship at the Dana-Farber Cancer Institute, both at Harvard Medical School.

Dr Socinski has held posts as Director of the Lung Cancer Section at the University of Pittsburgh Medical Center, Clinical Associate Director of the University of Pittsburgh Lung Cancer Specialized Program of Research Excellence (SPORE), Co-Director of UPMC Lung Cancer Center of Excellence, and Co-Leader of the Lung Cancer Program at the University of Pittsburgh Cancer Institute. He is a member of numerous professional societies, such as the American College of Physicians (ACP), American Society of Clinical Oncology (ASCO), Cancer and Leukemia Group B (Alliance), International Association for the Study of Lung Cancer (IASLC), and American College of Chest Physicians.

Dr Socinski is also co-Chair Emeritus of the Thoracic Malignancies Steering Committee for the National Cancer Institute. Dr Socinski is well-published in peer-reviewed literature, including the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer, and The Lancet Oncology. His primary research interests cover all aspects of clinical trials related to the thoracic oncology population. He also has been instrumental in the development of many cooperative group and investigator-initiated clinical trials.

Disclosures

Dr Socinski discloses that he has received grant support, honoraria and/or served on a speakers’ bureau for Genentech, Novartis, AstraZeneca, Spectrum, Guardant Health, and Bayer.